Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Micronized dehydrated human amnion chorion membrane (mdHACM) is a tissue-derived biologic allograft developed by MiMedx Group using the proprietary PURION® process. Derived from donated human placental tissues, it is processed into a micronized, injectable form that retains a complex milieu of signaling proteins, including growth factors and cytokines. mdHACM exhibits anti-inflammatory, anti-fibrotic, and regenerative properties. It is primarily developed for musculoskeletal conditions, where it aims to reduce pain and improve function by modulating inflammatory environments and promoting tissue homeostasis. Clinical development has focused on knee osteoarthritis and plantar fasciitis, with research also exploring its utility in tendinopathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on micronized dehydrated human amnion chorion membrane.